Obesity & OverweightNCT07444736
Effect of 8 Weeks of Resistance Training With Blood Flow Restriction on Muscle Strength, Clinical Parameters, Biochemical Biomarkers, and Perceived Exertion in Adults With Obesity
A study testing Intervention in people with Obesity & Overweight, run by Centro Universitario de Tlajomulco, Universidad de Guadalajara at 1 site in Mexico.
Trial summary
To analyze the effect of 8 weeks of resistance training with blood flow restriction on muscle strength, clinical parameters, biochemical biomarkers, and perceived exertion in adults with obesity. Read more about this study
- Who is it for?
- Ages 18 to 30 years
- Conditions the study is for
- Obesity & Overweight
- What is being tested?
- Intervention
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteMexico
- Study dates
- 1 Feb 2026to 15 May 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 30 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Adults aged 18 to 40
- Both genders
- BMI ≥ 30 kg/m^2 and < 40 kg/m^2
- Signed informed consent form
Who cannot join
- Participants who smoke
- Personal and family history of vascular disease or deep vein thrombosis
- Clinical diagnosis of hypothyroidism
- Clinical diagnosis of type 1 diabetes mellitus
- Clinical diagnosis of type 2 diabetes mellitus
- Clinical diagnosis of grade 3 obesity
Show all 15Show fewer
- Clinical diagnosis of hypertension
- Clinical diagnosis of acute myocardial infarction or angina pectoris
- Use of nitrates and calcium channel blockers within 4 days prior to the start of the study
- Use of anticoagulants
- Use of beta-blockers or hypoglycemic agents within 7 days prior to the intervention
- Pregnant women
- Breastfeeding women
- Men consuming more than 40 g of alcohol per day or women consuming more than 20 g per day
- Postural and biomechanical disorders (knee, foot, and spine)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Mexico1 site
Centro Universitario de Tlajomulco
Tlajomulco de Zúñiga, Jalisco, 45650
About this study
To analyze the effect of 8 weeks of resistance training with blood flow restriction on muscle strength, clinical parameters, biochemical biomarkers, and perceived exertion in adults with obesity.
Read the detailed description
Resistance training has been demonstrated to be an effective intervention for improving muscular strength and metabolic profile. According to the available evidence, a moderate-to-high intensity level (60-90% of one-repetition maximum [1RM]) is required to achieve optimal outcomes in healthy adults.
Blood flow restriction (BFR) training, in turn, has emerged as an innovative strategy that promotes gains comparable or similar to those achieved with moderate-to-high intensity resistance training. It has been proposed as an efficient and safe training alternative in both clinical and non-clinical settings . Current findings identify BFR as a promising, versatile, accessible, and particularly useful tool when moderate-to-high intensity resistance training must be limited or contraindicated.
Therefore, the present study aims to evaluate the effects of 8 weeks of resistance training combined with blood flow restriction on muscular strength, clinical parameters, biochemical biomarkers, and perceived exertion in adults with obesity, providing evidence regarding a potentially safe and effective intervention.
- Conditions
- Obesity & Overweight
- Being tested
- Intervention
- Keywords
- Obesity, Exercise
- Medical subject headings
- Obesity, Overweight, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
InterventionOther
The BFR group will perform machine-based quadriceps extension exercises and dumbbell biceps curls involving both lower limbs and both upper limbs. Each exercise will consist of 4 sets of 12 repetitions. Quadriceps extensions will be performed at an intensity of 40% of one-repetition maximum (1RM), and biceps curls at 20% of 1RM. The execution cadence will be standardized to 1 second for the concentric phase and 2 seconds for the eccentric phase. Inter-set rest intervals will be 1 minute. For vascular occlusion, a Carbafix cuff (8 cm width × 68 cm length for the upper limb; 10.5 cm width × 106.0 cm length for the lower limb) will be applied directly to the skin at the most proximal portion of the arm or thigh. The cuff will be inflated to 20 mmHg above resting brachial systolic blood pressure. To ensure partial vascular occlusion, pulse and oxygen saturation will be assessed using a pulse oximeter at the end of each set. Cuff pressure will be released during the inter-set rest periods.
InterventionOther
The control group will perform quadriceps extensions and biceps curls, completing 4 sets of 10 repetitions at an intensity of 70% of one-repetition maximum (1RM). The execution tempo will be standardized to 1 second for the concentric phase and 2 seconds for the eccentric phase, with 2-minute inter-set rest intervals. The protocol will adhere to the resistance training guidelines established by the American College of Sports Medicine (ACSM)
| Study group | Role | What they receive |
|---|---|---|
| BFR group | Experimental | This group will train for 8 weeks Receives: Other: Intervention |
| Control group | Active comparator | This group will train for 8 weeks Receives: Other: Intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Muscle strength
Muscle strength (kg): Change from baseline to 8 weeks of intervention. Muscle strength will be assessed using dynamometry
Measured: Baseline and after 8 weeks
Dynamic muscle strength
Dynamic muscle strength (kg): Change from baseline to 8 weeks of intervention.
Measured: Baseline and after 8 weeks
Arm circumference
Arm circumference (cm): Change from baseline to 8 weeks of intervention. Measurements will be obtained using a non-elastic measuring tape in accordance with the International Society for the Advancement of Kinanthropometry (ISAK) protocol
Measured: Baseline and after 8 weeks
Thigh circumference
Thigh circumference (cm): Change from baseline to 8 weeks of intervention. Measurements will be obtained using a non-elastic measuring tape in accordance with the International Society for the Advancement of Kinanthropometry (ISAK) protocol
Measured: Baseline and after 8 weeks
Maximum oxygen uptake (VO₂max)
VO₂max (ml/min/kg): Change from Baseline at 8 weeks, measured using a submaximal exercise test based on the Åstrand-Ryhming protocol
Measured: Baseline and after 8 weeks
Systolic blood pressure (SBP)
SBP (mmHg): Changes from baseline to 8 weeks of intervention
Measured: Baseline and after 8 weeks
Diastolic blood pressure (DBP)
DBP (mmHg): Changes from baseline to 8 weeks of intervention
Measured: Baseline and after 8 weeks
Heart rate
Heart rate (bpm): Change from baseline to 8 weeks of intervention.
Measured: Baseline and after 8 weeks
Glucose
Glucose (mg/dl): Changes from baseline to 8 weeks of intervention
Measured: Baseline and after 8 weeks
Triglycerides
Triglycerides (mg/dl): Changes from baseline to 8 weeks of intervention
Measured: Baseline and after 8 weeks
Total cholesterol
Total cholesterol (mg/dl): Changes from baseline to 8 weeks of intervention
Measured: Baseline and after 8 weeks
HDL cholesterol
HDL cholesterol (mg/dl): Changes from baseline to 8 weeks of intervention
Measured: Baseline and after 8 weeks
LDL cholesterol
LDL cholesterol (mg/dl): Changes from baseline to 8 weeks of intervention
Measured: Baseline and after 8 weeks
C-reactive protein (CRP)
CRP (mg/dl): Changes from baseline to 8 weeks of intervention
Measured: Baseline and after 8 weeks
Interleukin-6 (IL-6)
IL-6 (pg/mL):Change from baseline to 8 weeks of intervention.
Measured: Baseline and after 8 weeks
Tumor Necrosis Factor Alpha (TNF-α)
TNF-α (pg/mL): Change from baseline to 8 weeks of intervention
Measured: Baseline and after 8 weeks
Weight
Weight (kg): Changes in weight from baseline to 8 weeks of intervention.
Measured: Baseline and after 8 weeks
Height
Height (cm): Changes in height from baseline to 8 weeks of intervention
Measured: Baseline and after 8 weeks
Body mass index (BMI)
BMI (kg/m^2): Change from Baseline at 8 weeks, calculated by: weight (kg)/ height (m^2).
Measured: Baseline and after 8 weeks
Body fat percentage
Body fat percentage (%): Changes in body fat assessed by bioelectrical impedance analysis (BIA)
Measured: Baseline and after 8 weeks
Muscle mass percentage
Muscle mass percentage (%): Changes in muscle mass measured using bioelectrical impedance analysis (BIA)
Measured: Baseline and after 8 weeks
Perceived Exertion
Perceived exertion will be assessed using the Rating of Perceived Exertion Scale (RPE)
Measured: Baseline and after 8 weeks
Exercise enjoyment
Exercise enjoyment will be assessed using the validated Physical Activity Enjoyment Scale Questionnaire (PACES)
Measured: Baseline and after 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Mar 2026
- Study start1 Feb 2026 (estimated)
- Primary completion15 Mar 2026 (estimated)
- Study completion15 May 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Obesity & OverweightStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centro Universitario de Tlajomulco, Universidad de Guadalajara
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, José Manuel Pérez Casillas, Centro Universitario de Tlajomulco, Universidad de Guadalajara
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07444736
- Sponsor's protocol ID
- CUTLAJO260219
- Status last verified
- Feb 2026
- First submitted
- 25 Feb 2026
- Last updated
- 3 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of 8 Weeks of Resistance Training With Blood Flow Restriction on Muscle Strength, Clinical Parameters, Biochemical Biomarkers, and Perceived Exertion in Adults With Obesity
- ClinicalTrials.gov ID
- NCT07444736
- Acronym / sponsor ID
- CUTLAJO260219
- Conditions
- Obesity & Overweight
- Keywords
- Obesity, Exercise
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Centro Universitario de Tlajomulco, Universidad de GuadalajaraUniversity, hospital or other
- Study start
- 1 Feb 2026 (estimated)
- Primary completion
- 15 Mar 2026 (estimated)
- Study completion
- 15 May 2026 (estimated)
- First posted
- 3 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To analyze the effect of 8 weeks of resistance training with blood flow restriction on muscle strength, clinical parameters, biochemical biomarkers, and perceived exertion in adults with obesity.
Detailed description
Resistance training has been demonstrated to be an effective intervention for improving muscular strength and metabolic profile. According to the available evidence, a moderate-to-high intensity level (60-90% of one-repetition maximum [1RM]) is required to achieve optimal outcomes in healthy adults.
Blood flow restriction (BFR) training, in turn, has emerged as an innovative strategy that promotes gains comparable or similar to those achieved with moderate-to-high intensity resistance training. It has been proposed as an efficient and safe training alternative in both clinical and non-clinical settings . Current findings identify BFR as a promising, versatile, accessible, and particularly useful tool when moderate-to-high intensity resistance training must be limited or contraindicated.
Therefore, the present study aims to evaluate the effects of 8 weeks of resistance training combined with blood flow restriction on muscular strength, clinical parameters, biochemical biomarkers, and perceived exertion in adults with obesity, providing evidence regarding a potentially safe and effective intervention.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| BFR group | Experimental | Other: InterventionThis group will train for 8 weeks |
| Control group | Active comparator | Other: InterventionThis group will train for 8 weeks |
Who may qualify
- Ages
- 18 to 30 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Adults aged 18 to 40
- Both genders
- BMI ≥ 30 kg/m^2 and < 40 kg/m^2
- Signed informed consent form
Key exclusion criteria (15 listed)
- Participants who smoke
- Personal and family history of vascular disease or deep vein thrombosis
- Clinical diagnosis of hypothyroidism
- Clinical diagnosis of type 1 diabetes mellitus
- Clinical diagnosis of type 2 diabetes mellitus
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| InterventionThe BFR group will perform machine-based quadriceps extension exercises and dumbbell biceps curls involving both lower limbs and both upper limbs. Each exercise will consist of 4 sets of 12 repetitions. Quadriceps extensions will be performed at an intensity of 40% of one-repetition maximum (1RM), and biceps curls at 20% of 1RM. The execution cadence will be standardized to 1 second for the concentric phase and 2 seconds for the eccentric phase. Inter-set rest intervals will be 1 minute. For vascular occlusion, a Carbafix cuff (8 cm width × 68 cm length for the upper limb; 10.5 cm width × 106.0 cm length for the lower limb) will be applied directly to the skin at the most proximal portion of the arm or thigh. The cuff will be inflated to 20 mmHg above resting brachial systolic blood pressure. To ensure partial vascular occlusion, pulse and oxygen saturation will be assessed using a pulse oximeter at the end of each set. Cuff pressure will be released during the inter-set rest periods. | Other | BFR group |
| InterventionThe control group will perform quadriceps extensions and biceps curls, completing 4 sets of 10 repetitions at an intensity of 70% of one-repetition maximum (1RM). The execution tempo will be standardized to 1 second for the concentric phase and 2 seconds for the eccentric phase, with 2-minute inter-set rest intervals. The protocol will adhere to the resistance training guidelines established by the American College of Sports Medicine (ACSM) | Other | Control group |
Primary outcome
Muscle strength
Time frame: Baseline and after 8 weeks
Muscle strength (kg): Change from baseline to 8 weeks of intervention. Muscle strength will be assessed using dynamometry
Dynamic muscle strength
Time frame: Baseline and after 8 weeks
Dynamic muscle strength (kg): Change from baseline to 8 weeks of intervention.
Arm circumference
Time frame: Baseline and after 8 weeks
Arm circumference (cm): Change from baseline to 8 weeks of intervention. Measurements will be obtained using a non-elastic measuring tape in accordance with the International Society for the Advancement of Kinanthropometry (ISAK) protocol
Thigh circumference
Time frame: Baseline and after 8 weeks
Thigh circumference (cm): Change from baseline to 8 weeks of intervention. Measurements will be obtained using a non-elastic measuring tape in accordance with the International Society for the Advancement of Kinanthropometry (ISAK) protocol
Maximum oxygen uptake (VO₂max)
Time frame: Baseline and after 8 weeks
VO₂max (ml/min/kg): Change from Baseline at 8 weeks, measured using a submaximal exercise test based on the Åstrand-Ryhming protocol
Systolic blood pressure (SBP)
Time frame: Baseline and after 8 weeks
SBP (mmHg): Changes from baseline to 8 weeks of intervention
Diastolic blood pressure (DBP)
Time frame: Baseline and after 8 weeks
DBP (mmHg): Changes from baseline to 8 weeks of intervention
Heart rate
Time frame: Baseline and after 8 weeks
Heart rate (bpm): Change from baseline to 8 weeks of intervention.
Glucose
Time frame: Baseline and after 8 weeks
Glucose (mg/dl): Changes from baseline to 8 weeks of intervention
Triglycerides
Time frame: Baseline and after 8 weeks
Triglycerides (mg/dl): Changes from baseline to 8 weeks of intervention
Total cholesterol
Time frame: Baseline and after 8 weeks
Total cholesterol (mg/dl): Changes from baseline to 8 weeks of intervention
HDL cholesterol
Time frame: Baseline and after 8 weeks
HDL cholesterol (mg/dl): Changes from baseline to 8 weeks of intervention
LDL cholesterol
Time frame: Baseline and after 8 weeks
LDL cholesterol (mg/dl): Changes from baseline to 8 weeks of intervention
C-reactive protein (CRP)
Time frame: Baseline and after 8 weeks
CRP (mg/dl): Changes from baseline to 8 weeks of intervention
Interleukin-6 (IL-6)
Time frame: Baseline and after 8 weeks
IL-6 (pg/mL):Change from baseline to 8 weeks of intervention.
Tumor Necrosis Factor Alpha (TNF-α)
Time frame: Baseline and after 8 weeks
TNF-α (pg/mL): Change from baseline to 8 weeks of intervention
Weight
Time frame: Baseline and after 8 weeks
Weight (kg): Changes in weight from baseline to 8 weeks of intervention.
Height
Time frame: Baseline and after 8 weeks
Height (cm): Changes in height from baseline to 8 weeks of intervention
Body mass index (BMI)
Time frame: Baseline and after 8 weeks
BMI (kg/m^2): Change from Baseline at 8 weeks, calculated by: weight (kg)/ height (m^2).
Body fat percentage
Time frame: Baseline and after 8 weeks
Body fat percentage (%): Changes in body fat assessed by bioelectrical impedance analysis (BIA)
Muscle mass percentage
Time frame: Baseline and after 8 weeks
Muscle mass percentage (%): Changes in muscle mass measured using bioelectrical impedance analysis (BIA)
Perceived Exertion
Time frame: Baseline and after 8 weeks
Perceived exertion will be assessed using the Rating of Perceived Exertion Scale (RPE)
Exercise enjoyment
Time frame: Baseline and after 8 weeks
Exercise enjoyment will be assessed using the validated Physical Activity Enjoyment Scale Questionnaire (PACES)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Obesity & Overweight
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Intervention in people with Obesity & Overweight, run by Centro Universitario de Tlajomulco, Universidad de Guadalajara at 1 site in Mexico.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 3 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Mexico. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Muscle strength (time frame: Baseline and after 8 weeks). The study lists 23 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Mar 2026.